

Board of Directors Meeting in Public - Cover Sheet

Subject:	Q3 Research Quarterly Update		Date: 14/02/2018	
Prepared By:	Alison Steel, Research and Innovation Manager			
Approved By:	David Hodgson, Research and Innovation Director			
Presented By:	David Hodgson, Research and Innovation Director			
Purpose				
Quarterly summary of Q3 R&I metrics and benchmarking against 2016/17 performance			Approval	
Assurance of financial position at Q3 and update on 2018/19 indicative budgets			Assurance	
Identified risks to research development and growth at SFH highlighted			Update	X
Staffing update			Consider	
Summary of proposed developments and activity				
Strategic Objectives				
To provide outstanding care to our patients	To support each other to do a great job	To inspire excellence	To provide outstanding care to our patients	To support each other to do a great job
X			X	X
Overall Level of Assurance				
	Significant	Sufficient	Limited	None
		X		
Risks/Issues				
Financial	<ul style="list-style-type: none"> Reduction in EMCRN budget by 2.38% 2018/19 Missed opportunity to increase commercial revenue without a dedicated Clinical Research Facility Loss of ability to increase an element of EMCRN budget year on year due to risks of portfolio imbalance linked to lack of ability to conduct more interventional trials 			
Patient Impact	Decreased opportunity for our patient population to take part in research and access new and novel treatments			
Staff Impact	Creative use of funding in developing new trainee Band 5 research role and working together with Senior nurse leaders to fund research secondments			
Services				
Reputational	Currently have a strong reputation for research delivery across the region and have been praised for strengths in financial probity, overall recruitment and recruitment to time and target by the EMCRN. Risk this may be affected if research portfolio and complexity remains static			
Committees/groups where this item has been presented before				
Clinical Audit and Effectiveness Group meeting				
Executive Summary				
Recruitment performance in Research and Innovation at SFH continues to increase. At the 28 th December 2017:				
<ul style="list-style-type: none"> 1226 participants recruited in 17/18 compared to 665 in 16/17 Met and exceeded target to meet our goal of 1200 recruits by Q4 17/18 82 studies are open at SFH with 77 actively recruiting 				

- 100% of commercial and 72% of non-commercial studies are recruiting to 100% time and target
- Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Reproductive Health and Childbirth and Stroke.
- Charts 1-4 provide visual performance data
- Chart 5 provides complexity weighting for 17/18 recruitment

Research activity in the organisation is increasing year on year, giving more patients the opportunity to participate in studies allowing them access to novel treatments and interventions.

Commercial pharmaceutical and medical device research is also growing at SFH creating an excellent reputation for delivery with commercial sponsors, subsequently attracting new and renewed business.

Research and Innovation is meeting all its contractual obligations and reports quarterly to the Department of Health on "Performance and Initiation in Clinical Research" metrics which are publicly available

R&I received a 0.3% budget increase, (£731,162.40) due to high performance, despite a regional budget decrease of 3%. However, the indicative budget for 2018/19 is £714,137.55 based on a 2.38% reduction due to a national NIHR budget reduction.

An example of a particularly successful study at SFH in the last quarter was SPIRE - Saving Babies' Lives Project Impact and Results Evaluation. SFH was the highest recruiting site nationally with 11% of the total recruitment (213 patients and staff) delivered in just 3 weeks.

Areas of Risk highlighted to support development of a dedicated Clinical Research Facility

- Inability to expand portfolio of research opportunities for patients at their local hospital
- Reduced access for patients to new novel treatments
- Less attractive to commercial sponsors to open studies at SFH
- Lost opportunity to increase commercial income – Sites with a specific research facility attract an additional £1400 per study opened in addition to the study costs with 70% overhead.
- Inability to improve the environment and experience for patients taking part in research trials
- No option to improve research facilities for conducting trials that are already active
- Unable to expand research activity into Phase II or Phase III studies and increase the complexity of trials
- Impact on retention of staff and opportunity for further expansion of an integrated R&I function across the organisation

The use of advanced technologies in collecting, analysing and evaluating data in research is now widely used. Incompatibility between different institutions and organisations in terms of access to specific programmes, software and information technology can create barriers for NHS organisations wishing to participate in certain research trials.

Creative use of research funding for posts. Appointed a Band 5 Trainee Research Nurse/Midwife and funded 2 secondments (1 day a week for 12 months) for frontline clinical staff to work with the R&I team and access a research training programme.